ArticleCureus2025
Long-Term Effects of High-Intensity Interval Training (HIIT) on Cardiac Function and Mortality in Heart Failure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure (HF) is one of the causes of morbidity and mortality. High-intensity interval training (HIIT) has been suggested as a positive intervention that can be practiced to help optimize heart function and overall health. However, the effect of HIIT in the long-term on heart functioning, the level of symptoms shown by patients with HF, and the survival of the affected people are poorly understood. This study explores the effects of a long-term HIIT intervention on individuals who have HF.
methodsThis was a longitudinal observational study conducted in the cardiac department of Pakistan Institute of Medical Sciences (PIMS) in Islamabad, Pakistan, from July 2024 to January 2025. Purposive non-probability sampling was used to recruit all HF patients, with 158 patients aged 30 years and older participating. The demographic information and research instruments used at baseline, three months, and six months include the Kansas City Cardiomyopathy Questionnaire (KCCQ-12), Duke Activity Status Index (DASI) questionnaires, and New York Heart Association (NYHA) classification. IBM SPSS version 26 (IBM Corp., Armonk, NY, US) was used to conduct statistical tests, including repeated-measures ANOVA, Pearson correlation, and multiple linear regression.
resultsThe sample size consisted of 158 participants (N = 113, 71.0% men; N = 45, 29.0% women), with a mean age of 56.3 ± 12.4 years. There was a significant improvement in both KCCQ-12 and DASI (p < 0.01), whereas the NYHA classification worsened (p < 0.001). Increased levels of HIIT were associated with improved functional capacity and quality of life (r = 0.392, p < 0.01 for DASI; r = 0.215, p < 0.01 for KCCQ-12) and reduced symptom severity (r = -0.265, p < 0.01 for NYHA). The main predictors of these outcomes identified through regression analysis included HIIT, age, gender, and comorbidities. Gender differences were demonstrated by women reporting better outcomes and men exhibiting worse indicators concerning symptoms.
conclusionLong-term HIIT is highly effective in improving cardiac performance, decreasing the severity of HF symptoms, and improving the quality of life among HF patients. These findings demonstrate the promising potential of HIIT as an effective adjunctive treatment in managing HF, as it can bring significant benefits to patients of diverse ages and backgrounds. Early HIIT, tailored to the individual needs of each patient, has the potential to improve clinical outcomes and increase survival rates in HF populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.